Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mayne Pharma GroupMAYNF +5.26%52 3-1 Month Momentum % is -6.25% as of Aug. 01, 2026. GuruFocus rates MAYNF with a GF Score™ of 52/100 and a GF Value™ of $3.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 120 Medical Distribution companies, Mayne Pharma Group ranks better than 64.17% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-01), Mayne Pharma Group's 3-1 Month Momentum % is -6.25%.
The industry rank for Mayne Pharma Group's 3-1 Month Momentum % or its related term are showing as below:
MAYNF's 3-1 Month Momentum % is ranked better than 64.17% of 120
companies
in the Medical Distribution industry
Industry Median: -8.145
vs MAYNF: -6.25
Mayne Pharma Group (OTCPK:MAYNF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Mayne Pharma Group 3-1 Month Momentum % Related Terms
MAYNF vs MCK, COR, CAH: 3-1 Month Momentum % Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group 3-1 Month Momentum % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's 3-1 Month Momentum % falls into.
Mayne Pharma Group (OTCPK:MAYNF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (MAYNF) has a 3-1 Month Momentum % of -6.25% as of Aug. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #43 out of 120 companies in the Medical Distribution industry, placing it in the top 35.8%.
Is Mayne Pharma Group's 3-1 Month Momentum % too high?
Mayne Pharma Group's current 3-1 Month Momentum % is -6.25%. Based on the distribution chart, Mayne Pharma Group ranks #43 out of 120 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Mayne Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's 3-1 Month Momentum % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #43 out of 120 companies for 3-1 Month Momentum %. This puts Mayne Pharma Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Distribution company?
A good 3-1 Month Momentum % depends on the Medical Distribution industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Mayne Pharma Group and its competitors. Mayne Pharma Group's current 3-1 Month Momentum % is -6.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.70, compared to a current price of $2.00 — trading 45.9% below its estimated fair value. The current 3-1 Month Momentum % is -6.25%. Mayne Pharma Group's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current 3-1 Month Momentum % is -6.25% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $2.00 is trading 45.9% below its estimated GF Value™ of $3.70.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
3-1 Month Momentum %: -6.25%
GF Value™: $3.70 vs. price of $2.00 (45.9% below fair value)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
52GF Score
Get the complete analysis for MAYNF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
